newsfilter
← Latest News
ACCESS Newswire·

CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Cash expected to fund operations into the second half of 2026Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the blood-brain barrier,